title: Proteinuria associated with mTOR inhibitors after kidney transplant.
abstract: OBJECTIVE
  The mammalian target of rapamycin inhibitors sirolimus and everolimus are immunosuppressive drugs for kidney transplant patients, but adverse events may include proteinuria. The purpose of this study was to compare the effects of sirolimus and everolimus on creatinine clearance and proteinuria after kidney transplant.
  
  
  METHODS
  This study was a prospective evaluation period of 50 patients (age, 16-65 y) who had kidney transplant. There were 25 patients who used sirolimus and 25 patients who used everolimus. Evaluation at the beginning mTOR and end of the evaluation period included complete blood count, blood pressure, serum creatinine level, creatinine clearance, and proteinuria level in a 24-hour urine collection.
  
  
  RESULTS
  Mean creatinine clearance at the beginning and end of the evaluation period was significantly less in the everolimus than sirolimus group. There was no significant change in creatinine clearance from the beginning to end of the evaluation period in either the sirolimus or everolimus group. Mean proteinuria at the beginning and end of the evaluation period was similar between the sirolimus and everolimus groups. Both groups had a significant increase in mean proteinuria from beginning to end of the evaluation period, but the increase in proteinuria was similar for the sirolimus and everolimus groups (difference not significant).
  
  
  CONCLUSIONS
  In kidney transplant recipients, sirolimus and everolimus are associated with a similar level of increased mean proteinuria.
authors.affiliation: From the Department of Nephrology, Haydarpasa Research and Training Hospital, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Guney
authors.forename: Gulizar
authors.initials: G
authors.lastname: Sahin
authors.forename: Bilal
authors.initials: B
authors.lastname: Yilmaz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Canbakan
authors.forename: Murat
authors.initials: M
authors.lastname: Gucun
authors.forename: Kadir
authors.initials: K
authors.lastname: Kayatas
authors.forename: Pinar
authors.initials: P
authors.lastname: Eren
authors.forename: Izzet
authors.initials: I
authors.lastname: Titiz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D003404:Creatinine / Q000097:blood; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000175:diagnosis; D011446:Prospective Studies; D011507:Proteinuria / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D015415:Biomarkers; D007166:Immunosuppressive Agents; D000068338:Everolimus; D003404:Creatinine; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus